PSMA PET is considered a valuable tool for various aspects of patient care in the clinical management of prostate cancer and has shown promising results in initial staging of prostate cancer, localization of recurrent or persistent disease, and staging before PSMA-directed radioligand therapy. The gene discussed is FOLH1; the disease is prostate carcinoma.